Catalyst Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Catalyst Pharmaceuticals 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CPRX

Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company was founded by Hubert E. 

CEO
Richard John Daly
CEORichard John Daly
Employees
182
Employees182
Headquarters
Coral Gables, Florida
HeadquartersCoral Gables, Florida
Founded
2002
Founded2002
Employees
182
Employees182

CPRX Key Statistics

Market cap
3.02B
Market cap3.02B
Price-Earnings ratio
14.66
Price-Earnings ratio14.66
Dividend yield
Dividend yield
Average volume
1.43M
Average volume1.43M
High today
$24.94
High today$24.94
Low today
$24.50
Low today$24.50
Open price
$24.50
Open price$24.50
Volume
74.96K
Volume74.96K
52 Week high
$26.58
52 Week high$26.58
52 Week low
$19.05
52 Week low$19.05

Stock Snapshot

With a market cap of 3.02B, Catalyst Pharmaceuticals(CPRX) trades at $24.71. The stock has a price-to-earnings ratio of 14.66.

On 2026-03-05, Catalyst Pharmaceuticals(CPRX) stock moved within a range of $24.50 to $24.94. With shares now at $24.71, the stock is trading +0.9% above its intraday low and -0.9% below the session's peak.

Trading volume for Catalyst Pharmaceuticals(CPRX) stock has reached 74.96K, versus its average volume of 1.43M.

The stock's 52-week range extends from a low of $19.05 to a high of $26.58.

The stock's 52-week range extends from a low of $19.05 to a high of $26.58.

CPRX News

Nasdaq 22h
All You Need to Know About Catalyst Rating Upgrade to Strong Buy

Investors might want to bet on Catalyst Pharmaceutical (CPRX), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a r...

All You Need to Know About Catalyst Rating Upgrade to Strong Buy
Simply Wall St 1d
A Look At Catalyst Pharmaceuticals Valuation After Record 2025 Earnings And New 2026 Revenue Guidance

Advertisement Why Catalyst Pharmaceuticals (CPRX) Is On Investors’ Radar Now Catalyst Pharmaceuticals (CPRX) is in focus after reporting record Q4 and full ye...

A Look At Catalyst Pharmaceuticals Valuation After Record 2025 Earnings And New 2026 Revenue Guidance
TipRanks 2d
Buy Rating on Catalyst Pharma Driven by Strong 2026 Growth Outlook and Favorable Firdapse Litigation Upside

Analyst Samantha Semenkow of Citi maintained a Buy rating on Catalyst Pharma, with a price target of $35.00. Claim 50% Off TipRanks Premium Unlock hedge fund-le...

Analyst ratings

100%

of 7 ratings
Buy
100%
Hold
0%
Sell
0%

More CPRX News

TipRanks 3d
Buy Rating on Catalyst Pharma Backed by Strong Growth, Underpenetrated LEMS Opportunity, and Rising Profitability Post-Royalty Roll-Off

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Catalyst Pharma today and set a price target of $35.00. Andrew Fein has given his Buy rating due...

Simply Wall St 5d
Why Catalyst Pharmaceuticals Is Down 5.0% After Issuing 2026 Guidance And Buyback Plan - And What's Next

Catalyst Pharmaceuticals recently reported past fourth-quarter 2025 revenue of US$152.61 million and full-year revenue of US$588.99 million, alongside issuing 2...

Why Catalyst Pharmaceuticals Is Down 5.0% After Issuing 2026 Guidance And Buyback Plan - And What's Next

People also own

Based on the portfolios of people who own CPRX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.